12:29 : Salix Pharmaceuticals ([[SLXP]] +7.1%) spikes higher on volume 3X normal ... -
Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that ...
15:33 : Salix Pharmaceuticals ([[SLXP]] -5%) lags the market today after Stifel ... -
Salix Pharmaceuticals (SLXP -5%) lags the market today after Stifel Nicolaus cut the shares to Hold on valuation, noting it doesn't expect any significant outperformance from the stock, given an already impressive move coming ...
08:52 : Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report 'positive' highly -
Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, ...
12:39 : Salix Pharmaceuticals ([[SLXP]] +0.2%) says it's submitted a New Drug ... -
Salix Pharmaceuticals (SLXP +0.2%) says it's submitted a New Drug Application to the FDA for its HIV-induced diarrhea drug Crofelemer. The agency has 60 days to review the application and decide whether it will enter its review ...